Stifel Financial
TRVI icon

Stifel Financial’s Trevi Therapeutics TRVI Stock Holding History

Stifel Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Sell
25,102
-600
-2% -$8.73K ﹤0.01% 3012
2026
Q1 		$307K Sell
25,702
-2,586
-9% -$29K ﹤0.01% 3169
2025
Q4 		$354K Buy
28,288
+5,387
+24% +$62.3K ﹤0.01% 3049
2025
Q3 		$210K Buy
22,901
+2,250
+11% +$16.9K ﹤0.01% 3321
2025
Q2 		$113K Buy
20,651
+6,936
+51% +$43.2K ﹤0.01% 3351
2025
Q1 		$86.3K Buy
13,715
+2,700
+25% +$12.9K ﹤0.01% 3303
2024
Q4 		$45.4K Sell
11,015
-298
-3% -$954 ﹤0.01% 3321
2024
Q3 		$37.8K Sell
11,313
-990
-8% -$2.94K ﹤0.01% 3314
2024
Q2 		$36.7K Buy
12,303
+2,200
+22% +$6.11K ﹤0.01% 3296
2024
Q1 		$34.9K Buy
10,103
+3
+0% +$7 ﹤0.01% 3280
2023
Q4 		$13.5K Buy
+10,100
New +$15.3K ﹤0.01% 3283
2020
Q2 		– Sell
-13,845
Closed -$46K – 2948
2020
Q1 		$46K Sell
13,845
-10,707
-44% -$48.6K ﹤0.01% 2666
2019
Q4 		$91K Sell
24,552
-13
-0.1% -$49 ﹤0.01% 2895
2019
Q3 		$111K Buy
+24,565
New +$134K ﹤0.01% 2754

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Stifel Financial's TRVI Position: Q2 2026 in Review

Stifel Financial reduced its Trevi Therapeutics (TRVI) stake by 2.3% in Q2 2026, selling an estimated $8.73K and leaving 25,102 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Stifel Financial first reported a position in TRVI in Q3 2019 and has held it in 14 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Stifel Financial held 25,102 shares of Trevi Therapeutics worth $468K as of Q2 2026.
  • Stifel Financial sold 600 Trevi Therapeutics shares in Q2 2026, an estimated $8.73K.
  • Trevi Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #3012 holding.
  • Stifel Financial first reported a position in Trevi Therapeutics in Q3 2019 and has held it in 14 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.